NCT06993844 2026-03-17Phase 1/2 Study of ETX-636 in Participants With Advanced Solid TumorsEnsem TherapeuticsPhase 1/2 Recruiting233 enrolled
NCT03093116 2025-07-10TRIDENT-1Turning Point Therapeutics, Inc.Phase 1/2 Recruiting500 enrolled 2 FDA
NCT04104776 2025-05-15A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and LymphomasNovartisPhase 1/2 Recruiting275 enrolled